Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03906461 · ClinicalTrials.gov registry record
LSI (Lesion Index) Workflow Observational Study
A clinical trial of Paroxysmal Atrial Fibrillation, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 143
- Enrollment target
- 9
- Study locations
NCT03906461 is a study of Paroxysmal Atrial Fibrillation that has completed, run by Abbott Medical Devices. The registered enrollment target is 143 participants, below the 853-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (83% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT03906461, a study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 143 participants
- Enrollment target
- 9
- Study locations
Study Summary
This clinical study is a prospective, multicenter, post-market, single-arm, observational study designed to characterize the usage of the Lesion Index (LSI) with the market-released TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) in subjects with Paroxysmal Atrial Fibrillation (PAF) in a real-word environment.
Conditions Studied
Interventions
- DEVICE Radiofrequency Ablation
Study Locations (9)
Other
- St. Johannes Hospital - Dortmund
- Ospedale Santa Maria del Prato - Feltre
- Hospital Universitario de Monteprincipe - Boadilla del Monte
Tokyo
- Tokyo Medical and Dental University Hospital of Medicine - Bunkyō-Ku
- The Jikei University Katsushika Medical Center - Katsushikachō
California
- Mills-Peninsula Medical Center - Burlingame
Indiana
- St. Vincent Hospital - Indianapolis
Mississippi
- North Mississippi Medical Center - Tupelo
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2019-05-17 |
| Est. Completion | 2021-04-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03906461
The ClinicalTrials.gov registry entry for NCT03906461 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 853-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (83% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Ablation is the first listed.
NCT03906461 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, Tokyo, California.
Frequently Asked Questions
What is clinical trial NCT03906461 about?
NCT03906461 is a clinical study titled "LSI (Lesion Index) Workflow Observational Study". This clinical study is a prospective, multicenter, post-market, single-arm, observational study designed to characterize the usage of the Lesion Index (LSI) with the market-released TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) in subjects with Paroxysmal Atrial Fibrillati...
What is the current status of trial NCT03906461?
This trial is currently completed. The enrollment target is 143 participants. The study started on 2019-05-17. Estimated completion is 2021-04-27.
What conditions does trial NCT03906461 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT03906461?
The interventions under investigation include: Radiofrequency Ablation (DEVICE).
Who is sponsoring clinical trial NCT03906461?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03906461 being conducted?
This trial has 9 study locations across California, Indiana, Mississippi, New York, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
STOP AF First Post-Approval Study
RECRUITING
-
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
RECRUITING
-
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
RECRUITING
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.